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Abstract
Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor
cells, but does not affect normal cells or human leukemic cells, such as MOLT-4 and U937 cells, which are relatively
resistant to TRAIL. Three flavonoids extracted from the rhizome of K. parviflora were 5,7-dimethoxyflavone (DMF),
5,7,4’-trimethoxyflavone (TMF) and 3,5,7,3’,4’-pentamethoxyflavone (PMF), and synthetic flavonoids including 5-
methoxyflavone (5-MF) and 2’-methoxyflavone (2"-MF) were chosen for testing in this study. The aims of this study
were to examine whether the treatment of TRAIL-resistant leukemia MOLT-4 and U937 cells, with methoxyflavone
derivatives could enhance the apoptotic response and to identify the mechanism involved.
Methods: The cytotoxic effect of methoxyflavone (MF) derivatives in MOLT-4, U937 and peripheral blood
mononuclear cells (PBMCs) was analyzed by the MTT assay. The induction of apoptosis and the reduction of
mitochondrial transmembrane potential (ΔΨm) after staining with annexin V FITC and propidium iodide (PI), and
3,3’-dihexyloxacarbocyanine iodide (DiOC6), respectively, were performed using flow cytometry. ROS production
was determined by staining with 2’,7’-dichlorofluorescin diacetate and processed with a flow cytometer. DR4, DR5,
cFLIP, Mcl-1, BAX and Bid expression were demonstrated by immunoblotting. Caspase-8 and -3 activities were
determined by using IETD-AFC and DEVD-AFC substrates and the fluorescence intensity was measured.
Results: All methoxyflavone derivatives were cytotoxic to MOLT-4, U937 cells and PBMCs, except DMF, TMF and PMF
were not toxic to PBMCs. All MF derivatives induced human leukemic MOLT-4 cell apoptosis, but not in U937 cells.
Percentage of MOLT-4 cells with (ΔΨm) was increased when treated with DMF, TMF, PMF, 5-MF and 2’-MF in the
presence of TRAIL. 5-MF and 2’-MF enhanced TRAIL-induced apoptosis through the up-regulation of both DRs and the
down-regulation of cFLIP and Mcl-1. Bid was cleaved and BAX was up-regulated, followed by the activation of caspase-
8 and -3. Oxidative stress was also increased. 2’-MF gave the same result compared with 5-MF but with a less effect.
Conclusion: Methoxyflavone derivatives enhanced TRAIL-induced apoptosis in human leukemic MOLT-4 cells
through the death receptors and mitochondrial pathways.
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Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing
ligand receptors are type II transmembrane proteins.
They belong to TNF-R superfamily, having a short cyto-
plasmic N-terminal domain and a long C-terminal
extracellular receptor. They include TRAIL-R1 (DR4)
and TRAIL-R2 (DR5), which bind to ligands and induce
apoptosis. TRAIL-R3 (decoy receptor 1) and TRAIL-R4.
(decoy receptor 2), however, are non-apoptosis-inducing
receptors, because they lack a functional cytoplasmic
death domain [1]. TRAIL selectively induces apoptosis
in a variety of tumor cells, but is relatively non-toxic to
normal cells. Because of this, it is currently being used
in clinical trials for cancer treatment in combination
with various chemotherapeutic agents [2]. However,
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some tumor cells have been shown to be resistant to
TRAIL, such as MOLT-4 and U937 cells [3].
Methoxyflavones (MF) have been reported to contain
more chemopreventive activity than flavones [4]. Methox-
yflavone (MF) derivatives are groups of flavonoids contain-
ing various numbers of methoxy moieties, such as 2’-
methoxyflavone (2’-MF), 5-methoxyflavone (5-MF), 5,7-
dimethoxyflavone (DMF), 5,7,4’-trimethoxyflavone (TMF),
and 3,5,7,3’,4’,-pentamethoxyflavone (PMF). Reported
plant sources of these flavanoids include TMF, 5,7,3’,4’-tet-
raMF, 3,5,7,4’-tetraMF from Kaempferia parviflora [5,6];
and 5,3’-dihydroxy-3,6,7,8,4’-pentamethoxyflavone (DH-
PMF) from Gardenia obtusifolia [7]. The bioactivities of
MF derivatives include anti-inflammatory (5,7-DMF), anti-
malarial (TMF and 5,7,3’,4’-tetraMF), antifungal (3,5,7,4’-
tetraMF) [5]; antagonistic to aryl hydrocarbon receptor
(6,2’,4’-TMF) [8] and apoptosis inducing properties (5,3’-
dihydroxy-3,6,7,8,4’-pentamethoxyflavone) [7].
Flavonoids can induce apoptosis when combined with
TRAIL [9]. Thus, the aims of this study were to com-
pare the cytotoxic effects of methoxyflavone derivatives
on apoptotic induction alone and combined with TRAIL
in MOLT-4 and U937 cells, and to elucidate the




(TMF) and 3,5,7,3’,4’-pentamethoxyflavone (PMF), which
were isolated and purified from rhizomes of K. parviflora
as previously described [6]. 5-Methoxyflavone, 2’-meth-
oxyflavone, histopaque, MTT (3-(4,5-dimethyl)-2,5-
diphenyl tetrazolium bromide, propidium iodide (PI),
3,3’-dihexyloxacarbocyanine iodide (DiOC6) and 2’,7’-
dichlorofluorescin diacetate (DCFH-DA) were obtained
from Sigma-Aldrich (St. Louis, MO, USA). TRAIL was
obtained from R&D system, USA. RPMI-1640 medium,
DEVD-AFC (Asp-Glu-Val-Asp-7-amino-4-trifluoro-
methylcoumarin) and IETD-AFC (Ile-Glu-Thr-Asp-
amino-4-trifluoromethylcoumarin) were obtained from
Invitrogen, USA. Mouse monoclonal antibodies to Mcl-1,
BAX and rabbit polyclonal antibody to Bid, cFLIP and
horseradish peroxidase (HRP) conjugated secondary anti-
bodies were purchased from Abcam, Cambridge, UK.
Mouse monoclonal antibodies to beta-actin, DR4 and
DR5 were obtained from Santa Cruz Biotechnology,
USA. SuperSignal West Pico Chemiluminecent Substrate
was obtained from Pierce, Rockford, IL, USA. Annexin
V-Fluos staining kit and complete mini protease inhibitor
cocktail was obtained from Roche, Basel, Switzerland.
Cell culture
Human lymphoblastic leukemic MOLT-4 and monocytic
U937 cells were gifts from Professor Watchara Kasinroek
(Faculty of Associated Medical Sciences, Chiang Mai Uni-
versity). Peripheral blood mononuclear cells (PBMCs)
were donated from healthy volunteers. PBMCs were iso-
lated from heparinized blood by density gradient centrifu-
gation using histopaque according to standard protocols.
The blood was obtained from adult volunteers with Insti-
tutional Review Board approval, at Faculty of Medicine,
Chiang Mai University. The cells were cultured in RPMI-
1640 medium with 25 mM NaHCO3, 20 mM HEPES, 100
units/mL penicillin, 100 μ g/mL streptomycin and supple-
mented with 10% fetal bovine serum. The cell lines were
grown at 37°C in a 5% CO2 atmosphere. The PBMCs and
human leukemic cells (1 × 106) were treated with MF deri-
vatives at indicated concentrations and durations. MF
derivatives were dissolved in DMSO as a vehicle and the
maximal volume used did not exceed 10 μ l/ml of media.
Cytotoxicity test
Following MF derivative treatment, cell viability was
assessed by the MTT (3-(4,5-dimethyl)-2,5-diphenyl tetra-
zolium bromide) assay [10]. This method is based on the
ability of viable cells to reduce MTT and form a blue for-
mazan product. MTT solution (sterile stock solution of 5
mg/ml) was added to cell suspension at a final concentra-
tion of 100 μ g/ml and the solution incubated for 4 h at
37°C in a humidified 5% CO2 atmosphere. The medium
was then removed and cells were treated with DMSO for
30 min. The optical density of the cell lysate was measured
at 540 nm, with a reference wavelength of 630 nm, using a
microtiter plate reader (Biotek, USA). The number of
viable cells was calculated from the number of untreated
cells, and the data were expressed as percent cell viability.
Apoptosis assay
After treatment with methoxyflavone derivatives at a
concentration of IC20 for 0, 3, 6, 12, 18 and 24 h, the
cells were washed with PBS and centrifuged at 200 × g
for 5 minutes and suspended in 100 μ l of binding buf-
fer from a kit containing annexin V-FITC and PI, for 15
min. The samples were analyzed using a flow cytometer
(Beckton Dickinson, USA).
Determination of mitochondrial transmembrane potential
and ROS production
To measure mitochondrial membrane potential and
intracellular ROS, either 40 nM 3,3’-dihexyloxacarbocya-
nine iodide (for mitochondrial transmembrane potential
determination) or 5 μM 2’,7’-dichlorofluorescin diacetate
(for ROS detection) were added for 15 min at 37°C and
the cells were then subjected to flow cytometry.
Assay of caspase-3 and caspase-8 activity
Cleavage of the fluorogenic peptide substrates DEVD-
AFC and IETD-AFC was used to assay caspase-3-like
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and caspase-8-like enzyme activity. Cell lysates (1×106
cells) and substrate (50 μM) were combined in a stan-
dard reaction buffer and added to a 96-well plate.
Enzyme-catalyzed release of AFC was measured by a
fluorescence plate reader (Bio-tek, USA) using 355 nm
excitation and 460 nm emission wavelengths.
Western blot analysis
To obtain a cytosolic-rich fraction, MF derivative-trea-
ted cells were harvested and washed once in ice cold
PBS and incubated at 4°C for 10 min with ice-cold cell
lysis buffer (137 mM NaCl, 15 mM EGTA, 0.1 mM
Na2VO4, 15 mM MgCl2, 1% Triton X-100, with com-
plete mini protease inhibitor cocktail). The cell suspen-
sion was centrifuged at 20,000 × g for 20 min. The
supernatant was collected as the cytosolic-rich fraction.
Protein concentration of the cytosolic-rich fraction was
determined by the Bradford method. Cytosolic proteins
(50 μg) were separated by 17% SDS-PAGE and trans-
ferred onto nitrocellulose membranes. After treating
with 5% non-fat milk in TBS containing 0.2% Tween-20
(blocking buffer), membranes were incubated with
mouse monoclonal antibodies to DR4, DR5, BAX and
Mcl-1 and rabbit polyclonal antibody to Bid and cFLIP.
For detection, appropriate horseradish peroxidase (HRP)
conjugated secondary antibodies were used at 1:20,000
dilution. Protein bands were visualized on X-ray film
with SuperSignal West Pico Chemiluminecent Substrate.
Statistical analysis
Results were expressed as mean ± S.D. (standard devia-
tion). Statistical difference between control and treated
group was determined by a nonparametric one-way
ANOVA (Kruskal Wallis test) with a limit of p < 0.05 in
three independent experiments. For comparison between
two groups, data were analyzed using Student’s t-test.
Results
Cell cytotoxicity and apoptosis induction
All five MF derivatives were toxic to MOLT-4 and U937
cells with IC50 values as shown in Figure 1 and Table 1.
DMF, TMF and PMF were not cytotoxic to PBMCs
whereas 5-MF and 2’-MF were also toxic to PBMCs
(Figure 1). TRAIL was not cytotoxic to U937 and
MOLT-4 cells, viz. both cell lines were resistant to
TRAIL (Figure 2). The IC20 level of MF derivatives was
chosen for further experiments. In TRAIL combination
with MF, MOLT-4 cells were induced to die more in a
dose response manner (Figure 2).
5-MF induced MOLT-4 cell apoptosis mostly at 3 h
when combined with TRAIL for 24 h (Figure 3a) and 2’-
Methoxyflavone induced apoptosis (the time dependence
is shown in Figure 3b). Percent apoptotic cells increased
when combined with TRAIL compared to the absence of
Figure 1 Cytotoxic effects of DMF, TMF, PMF, 5-MF and 2’-MF
on human leukemic MOLT-4, U937 cell lines and PBMCs. MOLT-
4 or U937 or PBMC cells were treated with DMF or TMF or PMF, 5-
MF or 2’-MF at various concentrations for 24 h, then the cell viability
was determined by the MTT assay. *, p < 0.05, compared with
control.
Table 1 IC50 values of five methoxyflavone derivatives
(2’-methoxyflavone, 5-methoxyflavone, DMF, TMF and
PMF) in U937 and MOLT-4 cells
Methoxyflavone derivatives IC50 values (μ g/ml)*
U937 cells MOLT-4 cells
2’-MF 31.61 ± 0.68 30.11 ± 0.16
5-MF 46.70 ± 1.60 26.39 ± 2.22
DMF 24.56 ± 2.80 48.13 ± 5.12
TMF 12.95 ± 0.48 30.44 ± 0.52
PMF 19.28 ± 0.55 31.16 ± 2.22
*Means and standard deviations are calculated from triplicates of three
independent experiments.
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TRAIL. Meanwhile DMF, TMF and PMF also induced
MOLT-4 cell apoptosis synergistically to TRAIL (Figure
3c). Notably, all five MF derivatives and TRAIL synergisti-
cally induced MOLT-4 cell apoptosis, but this phenom-
enon did not occur in U937 cell line (data not shown).
Reduction of mitochondrial transmembrane potential
(MTP)
The percentage of MOLT-4 cells (treated with 5-MF
and/or TRAIL) with reduction of MTP was increased
more than those treated with 5-MF alone at 3, 6, 12, 18
and 24 h (Figure 4A). The combined treatment also
increased the cells with mitochondrial transmembrane
reduction compared to TRAIL alone.
For the 2’-MF treatment for 24 h without TRAIL,
percent cells with reduced mitochondrial transmem-
brane potential was increased compared to other incu-
bation time points. The percentage of cells with loss
of mitochondrial transmembrane potential signifi-
cantly increased when treated with TRAIL for 24 h
compared to TRAIL alone (control) as shown in Fig-
ure 4B.
Figure 2 Synergistic effects of 5-MF and 2’-MF when combined with TRAIL on MOLT-4 cytotoxicity. The cells were treated with IC20 of 5-
MF (A) or 2’-MF (B) for 24 h and then with various concentrations of TRAIL for 24 h, then cell viability was determined by the MTT assay and
compared with MF alone or TRAIL alone. *, p < 0.05, compared with control.
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Figure 3 Dot plot analysis of 5-MF or 2’-MF or DMF or TMF or PMF-treated MOLT-4 cells in the presence or absence of TRAIL. The
concentrations of 5-MF and TRAIL used were at IC20 levels. (a) The cells were untreated (A), treated with TRAIL for 24 h (B), 5-MF for 3 h (C), 5
MF for 3 h and TRAIL for 24 h (D), 5-MF for 6 h (E), 5-MF for 6 h and TRAIL for 24 h (F), 5-MF for 12 h (G), 5-MF for 12 h and TRAIL for 24 h (H),
5-MF for 18 h (I), 5-MF for 18 h and TRAIL for 24 h (J), 5-MF for 24 h (K) and 5-MF for 24 h and TRAIL for 24 h (L). (b) The MOLT-4 cells were
untreated (A), treated with TRAIL for 24 h (B), 2’-MF for 3 h (C), 2’-MF for 3 h and TRAIL for 24 h (D), 2’-MF for 6 h (E), 2’-MF for 6 h and TRAIL for
24 h (F), 2’-MF for 12 h (G), 2’-MF for 12 h and TRIAL for 24 h (H), 2’-MF for 18 h (I), 2’-MF for 18 h and TRIAL for 24 h (J), 2’-MF for 24 h (K) 2’-MF
for 24 h and TRAIL for 24 h (L). (c) The MOLT-4 cells were untreated (A), treated with TRAIL for 24 h (B), DMF for 24 h (C), DMF for 24 h plus
TRAIL for 24 h (D), TMF for 24 h (E), TMF for 24 h plus TRAIL for 24 h (F), PMF for 24 h (G) and PMF for 24 h plus TRAIL for 24 h (H). The cells
were stained with annexin V-FITC and PI, and processed by using flow cytometer. The percentages of early, late apoptotic cells and necrotic cells
are shown in the right lower quadrant, right upper quadrant and left upper quadrant, respectively.
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For DMF, TMF and PMF treatment for 24 h in com-
bination with TRAIL for another 24 h, the percentage of
cells with reduction of mitochondrial transmembrane
potential significantly increased when compared with
control or TRAIL alone (Figure 4C).
ROS production
Curcumin [11] and zerumbone [12] could induce cancer
cells to undergo apoptosis via the excessive production
of ROS. This led to the investigation of the ROS pro-
duction in MF derivative (5-MF and 2’-MF) treatment
in the MOLT-4 cells. When MOLT-4 cells were treated
with 5-MF and measured for ROS production, the fluor-
escence intensity of DCF increased, with the maximum
effect at 30 min treatment. For incubation with 2’-MF,
ROS was greatest at 60 min treatment (Figure 5).
The expression of TRAIL receptors (DR4 and DR5) and
apoptosis-related proteins
To determine how 5-MF and 2’-MF could facilitate
TRAIL-induced apoptosis, the effects of both MF deriva-
tives on TRAIL receptor (DR4 and DR5) expression
were determined. MOLT-4 cells were treated with 5-MF
or 2’-MF for various incubation times. The whole cell
extracts were prepared and examined for the expression
of DR4 and DR5. 5-MF induced both DR4 and DR5
(Figure 6A and 6B) expression in a time dependent
manner, whereas the expression of DR4 and DR5
induced by 2’-MF was unaltered (Figure 6C and 6D).
These results indicated that 5-MF up-regulated the
expression of both DR4 and DR5.
The treatment with 5-MF at various times (3, 6, 12, 18
and 24 h) resulted in a time dependent reduction in the
levels of antiapoptotic proteins cFLIP, Mcl-1 and an
increase in the proapoptotic protein BAX (Figure 7).
BH3 domain-only protein Bid (proform, 22 kDa) was
reduced due to the cleavage to obtain the truncated Bid
(tBid, 15 kDa). The 2’-MF treated cells had a lesser
effect on the reduction of Bid, antiapoptotic protein
Figure 4 Reduction of mitochondrial transmembrane potential
in MOLT-4 cells treated with MF derivatives in the presence or
absence of TRAIL. The cells were treated with 5-MF at IC20 level (A)
or 2’-MF at IC20 level (B) or DMF at IC20 level, TMF at IC20 level, PMF
at IC20 level (C) for various times of incubation and then with or
without TRAIL (IC20) for 24 h. After treatment the cells were
incubated with DiOC6 followed by flow cytometry as described in
the Methods. *, p < 0.05, compared with control, #, p < 0.05
compared to TRAIL alone.
Figure 5 Effect of 5-MF and 2’-MF on ROS production in MOLT-
4 cells. Cells were treated with 5-MF or 2’-MF for 30, 60 and 120
min and incubated with DCFH2-DA. The fluorescence intensity was
measured by a flow cytometer. Positive control is H2O2 treatment at
3%H2O2 for 3 min. *, p < 0.05, compared with control.
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cFLIP and Mcl-1 and an increase of BAX compared to
5-MF (Figure 7).
Caspase-8 and -3 activation
Caspase-8 is activated by association with death ligand
and receptor activation via the extrinsic pathway. In
MOLT-4 cells treated with 5-MF and TRAIL, caspase-8
activity increased at 3 and 6 h of 5-MF treatment (Fig-
ure 8A). For the 2’-MF and TRAIL treatment, the
caspase-8 activity increased between 18 and 24 h (Figure
8B). When MOLT-4 cells were treated with MF deriva-
tives alone, caspase-8 activity did not change. In the pre-
sence of TRAIL, 5-MF and 2’-MF induced MOLT-4 cell
apoptosis via the extrinsic pathway by activation of cas-
pase-8 activity.
Caspase-3 plays a central role in the apoptotic cas-
cade. When MOLT-4 cells were treated with 5-MF
combined with TRAIL, caspase-3 activity increased at 3,
Figure 6 Effect of 5-MF and 2’-MF on DR4 and DR5 expression in MOLT-4 cells. The cells were treated with each MF derivative (at IC20
level) for various times and then treated with TRAIL (IC20) for 24 h. The whole-cell extracts were prepared and analyzed by Western blotting
using anti-DR4 and anti-DR5 antibodies. DR4 (A) and DR5 (B) expression of MOLT-4 cells treated with 5-MF are shown. The cells were also
treated with 2’-MF for various times of incubation and TRAIL for 24 h, DR4 (C) and DR5 (D) expression are shown. The intensity of bands was
quantified by densitometry. *, p < 0.05, compared with control.
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6, 12, 18 and 24 h of treatment (Figure 8C). MOLT-4
cells treated with 2’-MF and TRAIL, had increased cas-
pase-3 activity at 3, 6, 12, 18 and 24 h of treatment (Fig-
ure 8D). However, when the cells were treated with MF
derivatives alone, caspase-3 activity was unaltered. In
the combined treatment, MOLT-4 cells were activated
to undergo apoptosis via caspase-3 activation.
Discussion
Recombinant human TRAIL has been recently recom-
mended for clinical trials in the treatment of human
cancer [13]. It selectively kills cancer cells while leaving
normal cells unharmed [14]. However, some cancer cells
are resistant to the TRAIL-induced apoptosis, such as
human leukemic U937 and MOLT-4 cells [3,15]. We
found that the methoxyflavone derivatives, DMF, TMF,
PMF, 5-MF and 2’-MF could facilitate TRAIL-induced
apoptosis in MOLT-4 cells (Figures 3 and 4). The apop-
totic cell death was confirmed by the externalization of
phosphatidylserine to the outer membrane of apoptotic
cells [16]. Ionizing radiation also sensitizes human leu-
kemic MOLT-4 cells to TRAIL-induced apoptosis [17].
Figure 7 Effect of 2’-MF and 5-MF on apoptosis-related protein expression in MOLT-4 cells. Immunoblot analysis was performed to
determine the expression levels of apoptosis-related proteins (c-FLIP, Mcl-1, BAX and Bid) after treatment with 2’-MF (A) and 5-MF (B) for various
times. The immunoblots are representatives of 3 independent experiments with similar results.
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5-MF and 2’-MF are methoxyflavones that are com-
mercially available where as DMF, TMF and PMF were
purified from rhizomes of K. parviflora. All five MFs
were able to induce and enhance the apoptosis induced
by TRAIL via the mitochondrial pathway (Figure 4).
The BAX proteins, which form homodimers on the
mitochondrial membrane, increased in expression, indi-
cating mitochondrial pathway involvement. ROS pro-
duction also occurred in the MF-induced apoptosis,
suggesting that it might involve the mitochondria (Fig-
ure 5). Fluorescence intensity was high at 30 min for 5-
MF and at 60 min for 2’-MF then it decreased after-
wards. The reason for this phenomenon might be that
each methoxyflavone derivatives could stimulate the
ROS production with the peaks at different rates. How-
ever, the mechanism remains to be clarified.
Mcl-1 is a BH-multidomain member of the Bcl-2
family that exhibits potent antiapoptotic activity and
plays a particularly important role in the survival of
malignant hematopoietic cells [18]. Mcl-1 modulates
apoptosis through multiple mechanisms, including
interactions with proapoptotic members of the Bcl-2
family such as BH3-only domain proteins, for example,
tBid [19]. Cooperation between activation of the intrin-
sic and extrinsic apoptotic pathways has been exten-
sively described [20]. Evidence that Mcl-1 plays a role in
controlling apoptosis by binding active Bid (tBid) there-
fore provides a theoretical basis for the observed syner-
gism between MF derivatives and TRAIL. For example,
in receptor-mediated induction of apoptosis, activation
of Bid represents a critical component of the cascade.
Following activation of procaspase-8 at the level of the
death inducing signaling complex (DISC), death signals
are transmitted to the mitochondria via cleavage of Bid
to generate tBid. tBid interacts with BAX and Bak to
promote their oligomerization and insertion into the
outer mitochondrial membrane, leading to mitochon-
drial outer membrane permeabilization.
5-MF induced both DR4 (Figure 6A) and DR5 (Figure
6B) in a time-dependent manner but no change was
observed for 2’-MF. To confirm this, we observed that
5-MF induced both DR4 and DR5 expression on the cell
Figure 8 Effect of 5-MF and 2’-MF on caspase-8 and -3 activities in MOLT-4 cells. Caspase-8 activity was measured in 5-MF- (A) and 2’-MF-
(B) treated cells for various times in the presence or absence of TRAIL for 24 h. The IETD-AFC substrate was cleaved and produced fluorescence.
Caspase-3 activity was measured in 5-MF- (C) and 2’-MF- (D) treated cells for various times and with or without TRAIL for 24 h. The DEVD-AFC
substrate was used. N-fold increase of fluorescence intensity was compared to that of untreated (control) cells, which was calculated to be 1. *, p
< 0.05, compared with control.
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membrane using immunocytochemistry (data not
shown).
In 5-MF/TRAIL- and 2’-MF/TRAIL-treated cells, cas-
pase-8 was activated. At this level, the most potent inhi-
bitor of caspase-8 is cFLIP, which is recruited along
with procaspase-8 and FADD/TRADD to the DISC.
cFLIP is a short-lived protein structurally related to pro-
caspase-8 but lacking enzymatic activity [21]. 5-MF and
2’-MF treatment induced a dramatic decrease in cFLIP,
which facilitated the activation of the extrinsic cascade.
It is possible that the simultaneous down-regulation of
Mcl-1 and cFLIP by 5-MF and 2’-MF might provide a
mechanism by which TRAIL-resistant leukemia MOLT-
4 cells were sensitized to these MF-derivatives. However,
the signaling effect of 2’-MF was less than that of 5-MF.
Clinical application of DMF, TMF, PMF, 5-MF and 2’-
MF is possible, although both 5-MF and 2’-MF were
toxic to PBMCs. The IC20 concentration levels of 5-MF
and 2’-MF induced human leukemic cell apoptosis with
no toxicity to normal cells. However, even though these
two methoxyflavone derivatives had a high potential
capacity to kill cancer cells, especially in the TRAIL
resistant human leukemic MOLT-4 cell type, the inves-
tigation in an in vivo model is needed before clinical
trials.
In conclusion, 5-MF could enhance TRAIL-induced
apoptosis through the up-regulation of both DRs and
the down-regulation of cFLIP and Mcl-1, followed by
the cleavage of Bid and activation of BAX. The caspase-
8 was activated through the extrinsic pathway, and fol-
lowed by activation of caspase-3. BAX oligomerization
at the mitochondrial membrane led to the reduction of
mitochondrial transmembrane potential. The mitochon-
drial pathway was also involved in activating caspase-3.
ROS production might be the result of mitochondrial
injury or the cause of mitochondrial signaling. 2’-MF
had a similar but lesser effect on the apoptotic signaling
pathway compared to 5-MF. DMF, TMF and PMF
could also synergistically enhance TRAIL-induced apop-
tosis via mitochondrial pathway.
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